March 16, 2020 / 12:01 PM / 15 days ago

BRIEF-Blueprint Medicines Announces Part 1 Results From Pioneer Trial Showing Broad Activity Of Avapritinib

March 16 (Reuters) - Blueprint Medicines Corp:

* BLUEPRINT MEDICINES ANNOUNCES PART 1 RESULTS FROM PIONEER TRIAL SHOWING BROAD ACTIVITY OF AVAPRITINIB ACROSS MEASURES OF MAST CELL BURDEN, CLINICAL OUTCOMES AND QUALITY OF LIFE IN INDOLENT SYSTEMIC MASTOCYTOSIS

* BLUEPRINT MEDICINES - AVAPRITINIB WAS WELL-TOLERATED WITH NO PATIENTS DISCONTINUING TREATMENT DUE TO ADVERSE EVENTS

* BLUEPRINT MEDICINES - AVAPRITINIB SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN PATIENT-REPORTED OUTCOMES

* BLUEPRINT MEDICINES CORP - PLANS TO INITIATE PATIENT SCREENING FOR REGISTRATION-ENABLING PART 2 OF PIONEER TRIAL IN JUNE 2020

* BLUEPRINT MEDICINES CORP - ANTICIPATES COMPLETING ENROLLMENT IN PART 2 OF PIONEER TRIAL BY END OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below